AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7851590 — intervention group
Group type: COMPARATOR
Intervention: Uterine transfer of cryopreserved embryos
Number of subjects: 40
Study 1723550 — intervention group
Group type: COMPARATOR
Intervention: KRN 8601 (75 micrograms/body, subcutaneous administration)
Number of subjects: 0
Study 1723550 — intervention group
Group type: EXPERIMENTAL
Intervention: KRN 8601 (25-800 micrograms/m2)
Number of subjects: 0
Study 1723550 — intervention group
Group type: EXPERIMENTAL
Intervention: KRN 8601 (100-200 micrograms/m2, intravenous drip infusion)
Number of subjects: 0
Study 1723550 — intervention group
Group type: COMPARATOR
Intervention: Inactive placebo
Number of subjects: 0
Study 7195890 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical treatment
Number of subjects: 71
Study 7195890 — intervention group
Group type: COMPARATOR
Intervention: Surgical-medical treatment (internal urethrotomy with antimicrobial agents)
Number of subjects: 71
Study 30660634 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine Position (SP)
Number of subjects: 347
Study 28762023 — intervention group
Group type: EXPERIMENTAL
Intervention: PVI group
Number of subjects: 60
Study 28762023 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 26372552 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannulated screw group (n = 16 patients, 16 feet)
Number of subjects: 31
Study 26372552 — intervention group
Group type: COMPARATOR
Intervention: Plate group (n = 15 patients, 16 feet)
Number of subjects: 31
Study 24530651 — intervention group
Group type: EXPERIMENTAL
Intervention: ForeseeHome (FH) device plus standard care
Number of subjects: 0
Study 24530651 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 0
Study 23208165 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive computer alerts for virologic failure and abnormal laboratory test results
Number of subjects: 1011
Study 23208165 — intervention group
Group type: COMPARATOR
Intervention: Static alerts for virologic failure and abnormal laboratory test results
Number of subjects: 1011
Study 23208165 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive computer alerts for suboptimal follow-up
Number of subjects: 1011
Study 23208165 — intervention group
Group type: COMPARATOR
Intervention: Static alerts for suboptimal follow-up
Number of subjects: 1011
Study 23208165 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive computer alerts after suboptimal follow-up alert
Number of subjects: 1011
Study 23208165 — intervention group
Group type: COMPARATOR
Intervention: Static alerts after suboptimal follow-up alert
Number of subjects: 1011
Study 23208165 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive computer alerts after toxicity alert
Number of subjects: 1011
Study 23208165 — intervention group
Group type: COMPARATOR
Intervention: Static alerts after toxicity alert
Number of subjects: 1011
Study 20051377 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulindac 150 mg daily for 6 weeks
Number of subjects: 30
Study 20051377 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulindac 150 mg twice daily for 6 weeks
Number of subjects: 30
Study 18931209 — intervention group
Group type: EXPERIMENTAL
Intervention: Cobra Perilaryngeal Airway (PLA)
Number of subjects: 200
Study 18931209 — intervention group
Group type: COMPARATOR
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 200
Study 16098887 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-nutritive sucking (NNS)
Number of subjects: 44
Study 16098887 — intervention group
Group type: COMPARATOR
Intervention: Control group (no NNS)
Number of subjects: 44
Study 12587520 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine (25 to 125 mg daily)
Number of subjects: 31
Study 9656160 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of coumarin
Number of subjects: 0
Study 9656160 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral administration of coumarin
Number of subjects: 0
Study 8122728 — intervention group
Group type: EXPERIMENTAL
Intervention: Short donation intervals (days 0, 3, 7, and 14)
Number of subjects: 40
Study 8122728 — intervention group
Group type: COMPARATOR
Intervention: Weekly donation intervals
Number of subjects: 40
Study 8122728 — intervention group
Group type: EXPERIMENTAL
Intervention: Short donation intervals (group I)
Number of subjects: 40
Study 8122728 — intervention group
Group type: COMPARATOR
Intervention: Weekly donation intervals (group II)
Number of subjects: 40
Study 2548815 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (4 mg twice daily by inhalation)
Number of subjects: 69
Study 2548815 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 956443 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 hour marathon group conducted by a female leader team
Number of subjects: 25
Study 956443 — intervention group
Group type: COMPARATOR
Intervention: No treatment control group
Number of subjects: 25
Study 31477797 — intervention group
Group type: COMPARATOR
Intervention: Yogurt consumption 1 time/week
Number of subjects: 24389
Study 31477797 — intervention group
Group type: COMPARATOR
Intervention: Yogurt consumption 2-3 times/week
Number of subjects: 24389
Study 31477797 — intervention group
Group type: COMPARATOR
Intervention: Yogurt consumption ≥4 times/week
Number of subjects: 24389
Study 31421685 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 74
Study 31421685 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 74
Study 27720794 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction for Breast Cancer (MBSR(BC)) program
Number of subjects: 322
Study 27720794 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 322
Study 25666288 — intervention group
Group type: EXPERIMENTAL
Intervention: Single intraoperative dose of 30 mg/kg tranexamic acid (OS group)
Number of subjects: 106
Study 25666288 — intervention group
Group type: COMPARATOR
Intervention: Loading dose of 10 mg/kg tranexamic acid followed by continuous 2 mg/kg/h infusion for 20 h (OD group)
Number of subjects: 106
Study 25666288 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (OS and OD)
Number of subjects: 106
Study 23480644 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand training for 12 weeks
Number of subjects: 35
Study 23480644 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 35
Study 21752319 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible bronchoscopy plus conventional medical treatment (lavage group)
Number of subjects: 60
Study 21752319 — intervention group
Group type: COMPARATOR
Intervention: Conventional medical treatment (control group)
Number of subjects: 60
Study 21752319 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible bronchoscopy (lavage group)
Number of subjects: 60
Study 18810487 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceiving a tone repetition
Number of subjects: 0
Study 18810487 — intervention group
Group type: EXPERIMENTAL
Intervention: Salient action effects
Number of subjects: 0
Study 18810487 — intervention group
Group type: COMPARATOR
Intervention: Non-salient action effects
Number of subjects: 0
Study 17077079 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic combination (L. rhamnosus GG, L. rhamnosus Lc705, P. freudenreichii ssp. shermanii JS, Bifidobacterium breve Bb99)
Number of subjects: 0
Study 17077079 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15001966 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg rifampin for 6 days
Number of subjects: 10
Study 15001966 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 11510872 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant incline-based protocol
Number of subjects: 8
Study 11510872 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant speed-based protocol
Number of subjects: 8
Study 11510872 — intervention group
Group type: COMPARATOR
Intervention: Both protocols
Number of subjects: 8
Study 11510872 — intervention group
Group type: COMPARATOR
Intervention: Higher inclines
Number of subjects: 8
Study 10405564 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with hypertension and cerebral stroke
Number of subjects: 36
Study 10405564 — intervention group
Group type: COMPARATOR
Intervention: Patients with primary hypertension without cerebral stroke (control group)
Number of subjects: 36
Study 8297699 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoprostenol (PGI2)
Number of subjects: 135
Study 8297699 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study 2465710 — intervention group
Group type: EXPERIMENTAL
Intervention: Mivacurium 0.15 mg/kg
Number of subjects: 54
Study 2465710 — intervention group
Group type: EXPERIMENTAL
Intervention: Mivacurium 0.20 mg/kg
Number of subjects: 54
Study 2465710 — intervention group
Group type: EXPERIMENTAL
Intervention: Mivacurium 0.25 mg/kg
Number of subjects: 54
Study 2465710 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 31402434 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based intervention (WI)
Number of subjects: 0
Study 31402434 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care condition
Number of subjects: 0
Study 31565753 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine (0.9 g kg‐1 fat‐free mass)
Number of subjects: 12
Study 31565753 — intervention group
Group type: COMPARATOR
Intervention: Placebo (CON)
Number of subjects: 12
Study 28487249 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of rightward prismatic adaptation (PA) and anodal transcranial direct current stimulation (tDCS) of the right motor cortex
Number of subjects: 34
Study 28487249 — intervention group
Group type: COMPARATOR
Intervention: Rightward prismatic adaptation (PA)
Number of subjects: 34
Study 28487249 — intervention group
Group type: COMPARATOR
Intervention: Anodal tDCS of the right motor cortex
Number of subjects: 34
Study 25205323 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferritin concentration (0.29 per log‐mg/dl)
Number of subjects: 4986
Study 25205323 — intervention group
Group type: EXPERIMENTAL
Intervention: Being an ethnic minority (‐0.24 compared with Kinh)
Number of subjects: 4986
Study 25205323 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of children (‐0.17)
Number of subjects: 4986
Study 25205323 — intervention group
Group type: EXPERIMENTAL
Intervention: Socioeconomic status (0.09)
Number of subjects: 4986
Study 25205323 — intervention group
Group type: EXPERIMENTAL
Intervention: RBP (0.27 per mg/dl)
Number of subjects: 4986
Study 25205323 — intervention group
Group type: EXPERIMENTAL
Intervention: Hookworm infection (‐0.11)
Number of subjects: 4986
Study 25205323 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalence of anemia
Number of subjects: 4986
Study 25205323 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron deficiency (Fe <12 μg/l)
Number of subjects: 4986
Study 25205323 — intervention group
Group type: EXPERIMENTAL
Intervention: Insufficient iron stores (Fe<30 μg/l)
Number of subjects: 4986
Study 25205323 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron deficiency anemia
Number of subjects: 4986
Study 23810354 — intervention group
Group type: COMPARATOR
Intervention: Manual lymphatic drainage (MLD) on days 2, 3, and 4 postoperatively
Number of subjects: 43
Study 23810354 — intervention group
Group type: COMPARATOR
Intervention: No manual lymphatic drainage (no MLD)
Number of subjects: 43
Study 21474643 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized ceftazidime (15 mg·kg(‐1)·3 h(‐1)) and amikacin (25 mg·kg(‐1)·d(‐1))
Number of subjects: 40
Study 21474643 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ceftazidime (90 mg·kg(‐1)·d(‐1), continuous administration) and amikacin (15 mg·kg(‐1)·d(‐1))
Number of subjects: 40
Study 18708923 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime (1.5 g preoperative dose)
Number of subjects: 1237
Study 18708923 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1237
Study 18708923 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime
Number of subjects: 1237
Study 18708923 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime and Placebo
Number of subjects: 1237
Study 16857835 — intervention group
Group type: EXPERIMENTAL
Intervention: L-rhamnose (25 g/d)
Number of subjects: 18
Study 16857835 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactulose (25 g/d)
Number of subjects: 18
Study 16857835 — intervention group
Group type: COMPARATOR
Intervention: D-glucose (control)
Number of subjects: 18
Study 11827905 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin (25 mg/kg, twice daily for 5 days)
Number of subjects: 1471
Study 11827905 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-trimoxazole (4 mg/kg trimethoprim plus 20 mg/kg sulphamethoxazole, twice daily for 5 days)
Number of subjects: 1471
Study 10419992 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg vitamin A
Number of subjects: 618
Study 10419992 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 618
Study 10419992 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg vitamin A (among malnourished infants)
Number of subjects: 618
Study 10419992 — intervention group
Group type: COMPARATOR
Intervention: Placebo (among malnourished infants)
Number of subjects: 618
Study 10419992 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg vitamin A (among well-nourished children)
Number of subjects: 618
Study 10419992 — intervention group
Group type: COMPARATOR
Intervention: Placebo (among well-nourished children)
Number of subjects: 618
Study 7570409 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol (50 micrograms twice daily)
Number of subjects: 63
Study 7570409 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 7570409 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol
Number of subjects: 63
Study 2111292 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed diet (1200 kcal/day)
Number of subjects: 110
Study 2111292 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactovegetarian diet (1200 kcal/day)
Number of subjects: 110
Study 2111292 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 110
Study 6767728 — intervention group
Group type: EXPERIMENTAL
Intervention: Helium particles
Number of subjects: 157
Study 6767728 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy charged particles (carbon, neon, argon ions)
Number of subjects: 157
Study 6767728 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy charged particles (helium, carbon, neon, argon)
Number of subjects: 157
Study 6344901 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg codeine
Number of subjects: 8
Study 6344901 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 8
Study 6344901 — intervention group
Group type: COMPARATOR
Intervention: 60 mg glaucine
Number of subjects: 8
Study 31335248 — intervention group
Group type: EXPERIMENTAL
Intervention: Visits involving discussion of chemotherapy
Number of subjects: 339
Study 31335248 — intervention group
Group type: EXPERIMENTAL
Intervention: Visits involving discussion of terminal prognosis
Number of subjects: 339
Study 31335248 — intervention group
Group type: EXPERIMENTAL
Intervention: Level of service
Number of subjects: 339
Study 31335248 — intervention group
Group type: COMPARATOR
Intervention: Provider characteristics (age, sex, years of experience)
Number of subjects: 339
Study 31335248 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimensions of work intensity
Number of subjects: 339
Study 29022754 — intervention group
Group type: EXPERIMENTAL
Intervention: PBM of 830 nm
Number of subjects: 30
Study 29022754 — intervention group
Group type: EXPERIMENTAL
Intervention: PBM of 685 nm
Number of subjects: 30
Study 26708755 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation (quitters, n=55)
Number of subjects: 434
Study 26708755 — intervention group
Group type: COMPARATOR
Intervention: Continued smoking
Number of subjects: 434
Study 26708755 — intervention group
Group type: COMPARATOR
Intervention: Smoking reduction (reduced intensity of smoking)
Number of subjects: 434
Study 26708755 — intervention group
Group type: COMPARATOR
Intervention: Smoking cessation or reduction
Number of subjects: 434
Study 24901838 — intervention group
Group type: EXPERIMENTAL
Intervention: Endorectal proctopexy with levatorplasty (ERPP)
Number of subjects: 66
Study 24901838 — intervention group
Group type: COMPARATOR
Intervention: STARR procedure
Number of subjects: 66
Study 22209591 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling with educational tools
Number of subjects: 261
Study 22209591 — intervention group
Group type: COMPARATOR
Intervention: Routine counseling procedures (Control)
Number of subjects: 261
Study 20434378 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually defined physiotherapy program
Number of subjects: 16
Study 20434378 — intervention group
Group type: COMPARATOR
Intervention: General training program
Number of subjects: 16
Study 19087327 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetes
Number of subjects: 64
Study 19087327 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired glucose tolerance (IGT)
Number of subjects: 64
Study 19087327 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired fasting glucose (IFG)
Number of subjects: 64
Study 19087327 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal glucose tolerance (NGT)
Number of subjects: 64
Study 16237616 — intervention group
Group type: EXPERIMENTAL
Intervention: Running (R)
Number of subjects: 13
Study 16237616 — intervention group
Group type: COMPARATOR
Intervention: Cycling (C)
Number of subjects: 13
Study 11818918 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric variable stiffness colonoscope
Number of subjects: 363
Study 11818918 — intervention group
Group type: COMPARATOR
Intervention: Pediatric colonoscope
Number of subjects: 363
Study 11818918 — intervention group
Group type: COMPARATOR
Intervention: Adult colonoscope
Number of subjects: 363
Study 11818918 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 363
Study 10419815 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA expression of cystic fibrosis (CF) gene
Number of subjects: 0
Study 10419815 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA expression of multidrug resistance (MDR1) gene
Number of subjects: 0
Study 10419815 — intervention group
Group type: COMPARATOR
Intervention: Control (other cell types within the villous core)
Number of subjects: 0
Study 7752174 — intervention group
Group type: EXPERIMENTAL
Intervention: celiprolol 200 mg or 400 mg once daily
Number of subjects: 171
Study 7752174 — intervention group
Group type: COMPARATOR
Intervention: metoprolol 100 mg or 200 mg once daily
Number of subjects: 171
Study 2178765 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemopreventive agents (natural and synthetic tumor suppressive retinoids and antioxidants)
Number of subjects: 0
Study 2178765 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemopreventive agents
Number of subjects: 0
Study 2178765 — intervention group
Group type: EXPERIMENTAL
Intervention: Candidate chemopreventives
Number of subjects: 0
Study 6107677 — intervention group
Group type: COMPARATOR
Intervention: Behaviour therapy
Number of subjects: 134
Study 6107677 — intervention group
Group type: COMPARATOR
Intervention: Pharmacotherapy (fenfluramine)
Number of subjects: 134
Study 6107677 — intervention group
Group type: COMPARATOR
Intervention: Combination of behaviour therapy and pharmacotherapy
Number of subjects: 134
Study 6107677 — intervention group
Group type: COMPARATOR
Intervention: Pharmacotherapy
Number of subjects: 134
Study 6107677 — intervention group
Group type: COMPARATOR
Intervention: Combination therapy
Number of subjects: 134
Study 30700250 — intervention group
Group type: EXPERIMENTAL
Intervention: DVD presentation along with standard invitation (letter and information leaflet)
Number of subjects: 1050
Study 30700250 — intervention group
Group type: COMPARATOR
Intervention: Standard invitation only (letter and information leaflet)
Number of subjects: 1050
Study 27668928 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab 0.3 mg
Number of subjects: 0
Study 27668928 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab 0.5 mg
Number of subjects: 0
Study 27668928 — intervention group
Group type: COMPARATOR
Intervention: Sham injections
Number of subjects: 0
Study 26026615 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally-tailored group format
Number of subjects: 98
Study 26026615 — intervention group
Group type: COMPARATOR
Intervention: Highly tailored, multidisciplinary individual format
Number of subjects: 98
Study 26026615 — intervention group
Group type: EXPERIMENTAL
Intervention: Group format
Number of subjects: 98
Study 26026615 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight concern
Number of subjects: 98
Study 24037008 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise program (3 times per week, 40 minutes per session, low-to-moderate intensity)
Number of subjects: 54
Study 24037008 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise program
Number of subjects: 54
Study 24037008 — intervention group
Group type: COMPARATOR
Intervention: Control group (dietary counseling aimed at reducing caloric intake by 100-300 calories per day)
Number of subjects: 54
Study 21294203 — intervention group
Group type: EXPERIMENTAL
Intervention: Passiflora incarnata herbal tea
Number of subjects: 41
Study 21294203 — intervention group
Group type: COMPARATOR
Intervention: Placebo tea
Number of subjects: 41
Study 18772894 — intervention group
Group type: EXPERIMENTAL
Intervention: CLA (3 g daily) plus n-3 LC-PUFA (3 g daily)
Number of subjects: 59
Study 18772894 — intervention group
Group type: COMPARATOR
Intervention: Control oil (6 g daily)
Number of subjects: 59
Study 17719337 — intervention group
Group type: EXPERIMENTAL
Intervention: Dofetilide
Number of subjects: 1511
Study 15213569 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonagachi Project intervention (community organizing, advocacy, peer education, condom social marketing, health clinic establishment)
Number of subjects: 200
Study 15213569 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonagachi Project intervention
Number of subjects: 200
Study 15213569 — intervention group
Group type: COMPARATOR
Intervention: Control community
Number of subjects: 200
Study 11926074 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant use
Number of subjects: 0
Study 11926074 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed heuristic definition of 'bipolar spectrum disorder'
Number of subjects: 0